CL2015000294A1 - Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa. - Google Patents
Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.Info
- Publication number
- CL2015000294A1 CL2015000294A1 CL2015000294A CL2015000294A CL2015000294A1 CL 2015000294 A1 CL2015000294 A1 CL 2015000294A1 CL 2015000294 A CL2015000294 A CL 2015000294A CL 2015000294 A CL2015000294 A CL 2015000294A CL 2015000294 A1 CL2015000294 A1 CL 2015000294A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitor
- pi3halpha
- optionally
- treatment
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680473P | 2012-08-07 | 2012-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015000294A1 true CL2015000294A1 (es) | 2015-05-08 |
Family
ID=48980368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015000294A CL2015000294A1 (es) | 2012-08-07 | 2015-02-06 | Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa. |
Country Status (39)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6342396B2 (ja) * | 2012-08-07 | 2018-06-13 | ノバルティス アーゲー | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
| ES2870716T3 (es) | 2013-03-21 | 2021-10-27 | Array Biopharma Inc | Terapia de combinación que comprende un inhibidor de B-RAF y un segundo inhibidor |
| WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| PL3155126T3 (pl) * | 2014-06-16 | 2019-01-31 | Worldwide Innovative Network | Sposób wybierania spersonalizowanej terapii potrójnej do leczenia nowotworu |
| WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
| JP2018525402A (ja) * | 2015-08-28 | 2018-09-06 | ノバルティス アーゲー | Ｐｉ３ｋ阻害剤のアルペリシブおよびｂ−ｒａｆ阻害剤のダブラフェニブを含む組合せ医薬、がんの治療または予防におけるそのような組合せの使用 |
| CN107921026A (zh) * | 2015-08-28 | 2018-04-17 | 诺华股份有限公司 | 药物组合物包含(a)α‑同种型特异性PI3K抑制剂alpelisib(BYL719)和(b)AKT抑制剂,优选MK‑2206,afuresertib或uprosertib及其在治疗/预防癌症中的应用 |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| KR102439911B1 (ko) | 2016-06-03 | 2022-09-05 | 어레이 바이오파마 인크. | 제약학적 복합제제 |
| JP7114575B2 (ja) | 2016-09-19 | 2022-08-08 | ノバルティス アーゲー | Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ |
| FI3618875T3 (fi) | 2017-05-02 | 2023-07-04 | Novartis Ag | Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito |
| JOP20200014A1 (ar) * | 2017-08-03 | 2022-10-30 | Novartis Ag | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf |
| KR20210125471A (ko) | 2018-10-05 | 2021-10-18 | 안나푸르나 바이오, 인코포레이티드 | Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물 |
| TWI849043B (zh) * | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| JP2022531969A (ja) | 2019-05-13 | 2022-07-12 | ノバルティス アーゲー | 癌を治療するためのＲａｆ阻害剤としてのＮ－（３－（２－（２－ヒドロキシエトキシ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－２－（トリフルオロメチル）イソニコチンアミドの新規な結晶形態 |
| GB2629956A (en) * | 2022-01-27 | 2024-11-13 | Univ Tohoku | Therapeutic agent for cancer |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024073364A1 (en) * | 2022-09-26 | 2024-04-04 | Beigene, Ltd. | Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO2008124161A1 (en) | 2007-04-10 | 2008-10-16 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| SG178866A1 (en) * | 2009-08-24 | 2012-04-27 | Genentech Inc | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| AU2010307043C1 (en) * | 2009-10-12 | 2014-03-13 | Glaxosmithkline Llc | Combination |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| TR201802943T4 (tr) * | 2010-11-08 | 2018-03-21 | Novartis Ag | (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. |
| US20140275174A1 (en) | 2011-11-10 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES |
| CN108542906A (zh) * | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| JP6342396B2 (ja) * | 2012-08-07 | 2018-06-13 | ノバルティス アーゲー | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
-
2013
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en not_active Ceased
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/en active Pending
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active Active
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 HK HK15110834.2A patent/HK1211831A1/xx unknown
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 PH PH12015500246A patent/PH12015500246A1/en unknown
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015000294A1 (es) | Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa. | |
| IL285843A (en) | Ibrutinib for use in the treatment of chronic graft versus host disease | |
| CL2015000345A1 (es) | Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. | |
| IT1400425B1 (it) | Modified snrnas for use in therapy. | |
| HRP20181364T1 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112012031232A2 (pt) | método, dispositivo e uso | |
| LT2894151T (lt) | Imidazolino dariniai, jų gamybos būdai ir jų naudojimas medicinoje | |
| PL2831055T3 (pl) | Zdolne do polimeryzacji alkilideno-1,3-dioksolan-2-ony i ich zastosowanie | |
| DK3065764T6 (da) | Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling | |
| CL2014001337A1 (es) | Formulacion farmaceutica oral solida que comprende una dispersion solida que comprende a su vez un compuesto especifico derivado de 4-(1-isopropil-1h-pirazol-4-il)-pirimidina y su uso en el tratamiento de una enfermedad proliferativa. | |
| SG10201802430VA (en) | Dna-binding protein using ppr motif, and use thereof | |
| ES1110832Y (es) | Orinal desechable y plegable. | |
| CL2014003525A1 (es) | Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension. | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| DK2816947T3 (da) | Endoskopisk anordning, særlig til medicinsk brug | |
| CL2013003198A1 (es) | Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas. | |
| BR112013012175A2 (pt) | combinação, coadministração, uso e método | |
| CL2014001323A1 (es) | Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| ES1078238Y (es) | Dosificador ocular para colirios, sueros y otros liquidos de uso higienico o medicinal | |
| GB201310921D0 (en) | Peptide-resin conjugate and use thereof | |
| BR112012028533A8 (pt) | cateter e seu uso, método para iniciar pleurodese e método para irritar ou enrugar uma superfície | |
| BRPI0907700A2 (pt) | Imidazopiridazinas como inibidores par1, produção das mesmas e uso como medicamentos | |
| IL280316B (en) | Bolaamphiphilic compounds, compositions and uses thereof | |
| EP3185826A4 (en) | Acrylic polymers and their use in transdermal drug delivery |